A phase 1b trial targeting TAMs with a CCR2 inhibitor (PF-04136309) in combination with FOLFIRINOX in patients with stage III pancreatic cancer reported a promising, high objective tumor response rate. This evidence concerns the gene CCR2 and familial pancreatic carcinoma.